Heiq Share Discussion Threads

[wingrove4] 30/12/2020 09:42

My best pick in a long time up 45% in 3 weeks. I have set a 300p price target, any thoughts?

[jammytass] 29/12/2020 17:16

good start to this still under the radar of many
when a few good rns come out watch it fly £5.00 target end 2021

[lazygun] 29/12/2020 13:00

Spanish mask company , capacity of 180 million masks annually.....

And that’s just one part of their business......

L

[rolo7] 29/12/2020 12:36

Product being used in swizz hotel to protect guess from covid on heiq website

[jammytass] 29/12/2020 11:38

Steady rise would be nice

[rolo7] 29/12/2020 08:21

ledgeable for Small cap index entry in match?

[sranmal] 26/12/2020 17:05

This is still massively under the radar IMO, hope it stays that way for a while longer as it ticks up. Two main points for me from presentation on website - medium term goal to grow revenue from $30M to $300M, and ViroBlock at "tipping point for massive growth".

[davidosh] 26/12/2020 11:33

HeiQ was highlighted on the End of Year Mello Monday last week.

[jammytass] 25/12/2020 17:44

looks like a few of us will be in at the start 2x bagger in 2021

bloc hotel;
To keep you safe in all of our rooms and communal areas, we’ve partnered with scientists at HeiQ to coat all our surfaces with Viroblock - a groundbreaking technology that is scientifically proven to be 99.99% effective at destroying harmful viruses, including COVID-19.

[pastybap] 22/12/2020 09:50

It was discussed last night by Leon Boros at Mello Monday. He expects a significant earnings beat in H2.

[argy4] 22/12/2020 09:29

Starting to react, news soon?

[shavian] 16/12/2020 16:56

Nice finish today, but we are still flying well under the radar.

[argy4] 16/12/2020 14:13

MASSIVE POTENTIAL:

HeiQ Plc

Concludes acquisition of majority stake in Spanish medical device manufacturer

HeiQ Plc (LSE:HEIQ), an established global brand in materials and textile innovation which operates in high-growth markets, is pleased to announce that it has completed the acquisition of a majority stake in a leading Spanish mask manufacturer, MasFabEs, further to entering into a joint venture outlined in the Company's Prospectus. The manufacturer has been renamed HeiQ Medica S.L. and will manufacture medical devices with HeiQ's cutting-edge textile technologies.

MasFabEs has already been producing OTC (over the counter) medical device Type IIR surgical masks (certified for use in a close clinical environments), enhanced with HeiQ Viroblock technology, since the beginning of the pandemic. To date, over 1 billion community face coverings as well as medical masks enhanced with HeiQ Viroblock technology have been sold and the technology is already being used by more than 150 major mask brands such as Burberry.



The Company continues to experience strong demand for surgical masks which benefit from the extra protection provided by its Swiss Technology Award-winning HeiQ Viroblock technology. With a maximum production capacity of 15 million masks per month, enough to cover the needs of entire Switzerland with two masks a day, this acquisition will provide HeiQ with more control over the manufacture of its products. It will also provide the Company with an ideal base from which to establish an R&D hub for medical devices in Europe. Bulk order supply will be prioritised for institutions in the medical and healthcare sectors, such as hospitals, clinics, pharmacies and care homes. The masks will also be available on HeiQ's direct to consumer webshop.



HeiQ co-founder and CEO Carlo Centonze said:

"As a leading, profitable player in the $10 billion antimicrobial market, this manufacturing capability will ensure that we are well positioned to meet the strong on-going demand that we are experiencing for our products. The acquisition is in line with our stated strategy to deliver shareholder value by building on the significant momentum achieved by HeiQ Viroblock while also growing other innovations within our core product portfolio. The pandemic has changed our behaviour for good. Following the SARS epidemic in Asia in 2003, all medical and healthcare workers now use face masks daily in this region and we are confident that this practice will continue worldwide even when the Covid-19 pandemic is under control.



"The third pillar of our growth strategy is focused on launching new high margin innovations which serve high growth markets. We are working on a range of exciting technologies, including a new antimicrobial technology with our long standing Australian partner Xefco, as well as our graphene membrane innovation. We look forward to sharing news of a number of exciting advancements ongoing within our R&D pipeline in the coming months."

Pedro Herranz, Co-founder and General Manager of MasFabEs, said:

"As a company that was founded expressly to provide "made in Spain" products, hence the name MasFabEs (Mascarillas de Fabricación Española), we were already producing HeiQ Viroblock powered masks and enjoyed an excellent relationship with HeiQ. Their majority participation, distribution reach and their plans for applying their materials innovations to medical devices were received with open arms and we are excited about future developments."

[shavian] 15/12/2020 10:04

And off we go to the races.

[shavian] 09/12/2020 09:42

I asked Transact yesterday morning at 8am to add HEIQ to their platform. They emailed me back at 1120 to say it was there. Cracking service as ever.

[oshy92] 07/12/2020 16:12

Hi all. Short TV clip with HEIQ Founders about the company:

www.youtube.com/watch?v=IOj10X0j_7o

[sranmal] 07/12/2020 12:56

They said they'll email me when it's added. In the meantime, there's an interesting presentation on their website (and prospectus).
heiq.com/investors/

[saj3] 07/12/2020 12:50

I was just about to ask same question also had problem with IG

[sranmal] 07/12/2020 12:19

Had to contact IG to ask them why they weren't quoting it - said it will take 1-3 days to get it added! Would have thought in this day and age, it should be 8am on day of listing.

[rat attack] 07/12/2020 10:29

Introduction and placing today @ 112p

HeiQ is a leader in textile innovation creating some of the most effective, durable and high-performance textile effects in the market today.

Interesting aspect is HeiQ Viroblock NPJ03 tested effective against SARS-CoV-2 (COVID-19). HeiQ Viroblock NPJ03 is an antiviral and antibacterial textile treatment – a unique combination of silver and vesicle technologies designed to significantly reduce viral and bacterial infectivity on treated surfaces.